Rafael Holdings, Inc. (RFL), reported a year-over-year loss for its third quarter of fiscal year 2026, ended April 30, 2026, reflecting a narrower net loss. Company Profile
Rafael Holdings is a clinical and early-stage biopharmaceutical company focused on the development and commercialization of therapies for oncology and rare diseases.
The company's lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials as a potential treatment for Niemann-Pick Disease Type C1, a rare, fatal, and progressive genetic disorder.
Third Quarter 2026 Results:
For the third quarter, the company recorded a net loss of $4.23 million, or $0.08 per share, versus a net loss of $4.78 million, or $0.19 per share in the year-ago period.
Revenue dropped to $0.18 million, down by 50% from $0.36 million in the prior year.
As of April 30, 2026, cash and cash equivalents totalled $30.5 million.
RFL is currently trading at $2.33, up 10.25%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.